Black Diamond Therapeutics, Inc.
BDTX
$2.85
$0.020.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.67% | -31.32% | -31.79% | -4.71% | 1.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.37% | -28.54% | -25.16% | -13.08% | -8.88% |
| Operating Income | 125.22% | 114.57% | 105.39% | 95.30% | 8.88% |
| Income Before Tax | 132.10% | 129.41% | 117.93% | 106.38% | 15.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 132.10% | 129.41% | 117.93% | 106.38% | 15.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.10% | 129.41% | 117.93% | 106.38% | 15.48% |
| EBIT | 125.22% | 114.57% | 105.39% | 95.30% | 8.88% |
| EBITDA | 125.75% | 115.06% | 105.81% | 95.68% | 8.82% |
| EPS Basic | 131.32% | 127.88% | 116.51% | 104.65% | 33.97% |
| Normalized Basic EPS | 139.70% | 125.77% | 114.87% | 103.40% | 32.81% |
| EPS Diluted | 129.42% | 126.13% | 114.78% | 103.32% | 33.73% |
| Normalized Diluted EPS | 138.36% | 124.52% | 113.76% | 102.39% | 32.81% |
| Average Basic Shares Outstanding | 3.37% | 5.53% | 8.13% | 17.83% | 25.34% |
| Average Diluted Shares Outstanding | 3.82% | 6.00% | 8.61% | 18.35% | 25.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |